Isopropyl 2-(acetylamino)-2-deoxyhexopyranoside

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Isopropyl 2-(acetylamino)-2-deoxyhexopyranoside
• 英文别名: N-[4,5-dihydroxy-6-(hydroxymethyl)-2-propan-2-yloxyoxan-3-yl]acetamide
• 化学式: C₁₁H₂₁NO₆
• 分子量: 263.29
• InChiKey: CSHJQINNMOQHDM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  108
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• OLIGONUCLEOTIDE DERIVATIVE, OLIGONUCLEOTIDE CONSTRUCT USING THE SAME, AND METHODS FOR PRODUCING THEM
  申请人：GIFU UNIVERSITY

  公开号：US20180094017A1

  公开（公告）日：2018-04-05

  The oligonucleotide derivative of the present invention is represented by Formula (1). This derivative is considered to be introduced into cells by binding of its amino sugar chain moiety to a ligand on cell surfaces, and have selective drug delivery function. The oligonucleotide derivative can be easily synthesized and introduced into cells without using a lipofection reagent. wherein—A and B are independently modified or unmodified oligonucleotides whose total chain length is 3 or more, and A and B do not contain hydroxyl groups at 3′ and 5′ ends of the oligonucleotide; S represents a sugar substituent, a peptide chain, or a tocopherol-binding group; and an alkyl group may be bound instead of hydrogen bound to a benzene ring.

  本发明的寡核苷酸衍生物由式（1）表示。该衍生物被认为通过其氨基糖链部分与细胞表面的配体结合而被引入细胞，并具有选择性药物传递功能。该寡核苷酸衍生物可以在不使用脂质体载体的情况下轻松合成并引入细胞。其中，A和B分别是经修饰或未经修饰的寡核苷酸，其总链长为3或更长，且A和B不含有寡核苷酸的3′和5′末端的羟基；S代表糖取代基、肽链或生育酚结合基；和烷基基团可以与苯环上的氢结合而不是氢结合。
• Compositions and methods for modulating complement factor B expression
  申请人：Ionis Pharmaceuticals, Inc.

  公开号：US10280423B2

  公开（公告）日：2019-05-07

  The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with dysregulation of the complement alternative pathway by administering a Complement Factor B (CFB) specific inhibitor to a subject.

  本发明的实施方案提供了通过向受试者施用补体因子B（CFB）特异性抑制剂来治疗、预防或改善与补体替代途径失调相关的疾病的方法、化合物和组合物。
• Compositions and methods for modulating PKK expression
  申请人：Ionis Pharmaceuticals, Inc.

  公开号：US10294477B2

  公开（公告）日：2019-05-21

  Disclosed herein are antisense compounds and methods for decreasing PKK mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate PKK-associated diseases, disorders, and conditions.

  本文公开了减少 PKK mRNA 和蛋白质表达的反义化合物和方法。这些方法、化合物和组合物可用于治疗、预防或改善与 PKK 相关的疾病、失调和病症。
• Conjugated antisense compounds and their use
  申请人：Ionis Pharmaceuticals, Inc.

  公开号：US10570169B2

  公开（公告）日：2020-02-25

  Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the gomeric compounds are conjugated to N-Acetylgalactosamine or to N-Acetylgalactosamine analogues.

  本文提供的是具有共轭基团的低聚化合物。在某些实施方案中，低聚物与 N-乙酰半乳糖胺或 N-乙酰半乳糖胺类似物共轭。
• Glucose conjugates of triptolide, analogs and uses thereof
  申请人：The Johns Hopkins University

  公开号：US10695319B2

  公开（公告）日：2020-06-30

  Provided are compounds generated by conjugation of triptolide with glucose to form glucose-triptolide conjugates, provides compounds with effective anti-proliferative activity and improved tolerability as compared to naturally occurring triptolide compounds.

  本研究提供了通过三苯内酯与葡萄糖共轭形成葡萄糖-三苯内酯共轭物而生成的化合物，与天然存在的三苯内酯化合物相比，这些化合物具有有效的抗增殖活性和更好的耐受性。